BofA lifted its price target to $27 from $24 while keeping an 'Underperform' rating on the shares. ・The update followed the ...

If promising results on a skin cancer vaccine from Moderna and Merck lead to a new launch, the Covid-19 era darling's stock ...

Moderna CEO Stéphane Bancel positions 2026 as a catalyst-rich year driven by new vaccine launches, late-stage oncology data, ...

Moderna (MRNA) has reiterated its target of up to 10% revenue growth in 2026, supported by a strategy to build a large ...

Moderna and Merck previously reported five-year follow-up data from their Phase 2b KEYNOTE-942 trial, showing that the ...

While Moderna’s full-year sales landed in the upper end of its target range, Jefferies analysts said further reductions are ...

We recently published 10 Stocks Jim Cramer Talked About. Moderna Inc. (NASDAQ:MRNA) is one of the stocks on Jim Cramer talked ...